XM
ONCT

XTX Markets’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

XTX Markets’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$53K Buy
+538
New +$34K 0.11% 180

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

XTX Markets's ONCT Position: Q4 2020 in Review

XTX Markets opened a new position in Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2020: 538 shares worth $53K. The stake represents 0.11% of the portfolio and ranks #180 among its holdings.

52 funds tracked by Wall St. Rank hold ONCT as of Q4 2020.

  • XTX Markets held 538 shares of Oncternal Therapeutics, Inc. Common Stock worth $53K as of Q4 2020.
  • Oncternal Therapeutics, Inc. Common Stock was a new XTX Markets position in Q4 2020.
  • Oncternal Therapeutics, Inc. Common Stock made up 0.11% of XTX Markets's portfolio in Q4 2020, its #180 holding.
  • 52 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2020.

Based on XTX Markets's 13F filing for Q4 2020, filed 25 Jan 2021.